Business Context and Reporting Period
Gossamer Bio, Inc. (GOSS) filed a Form 8-K Current Report on August 24, 2026. The filing addresses corporate governance changes related to a private placement transaction.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on legal and structural amendments rather than financial performance data.
Material Changes
- Amendment to Articles of Incorporation: On August 24, 2026, the Company amended its amended and restated certificate of incorporation.
- Series A-1 Preferred Stock: The Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A-1 Convertible Preferred Stock with the Delaware Secretary of State.
- Context: These actions were taken in connection with the closing of a previously announced private placement.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document references a prior Form 8-K filed on August 21, 2026, for details regarding the rights and preferences of the new stock series.
Investor Verification Checklist
- Verify the specific terms, conversion rates, and liquidation preferences of the Series A-1 Convertible Preferred Stock in the referenced August 21, 2026 filing and Exhibit 3.1.
- Confirm the total capital raised and the number of shares issued in the private placement closing.
- Assess the dilution impact of the Series A-1 issuance on existing common stockholders.
- Review the Company's cash runway post-closing to understand the funding's impact on operational liquidity.